Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

Research output: Contribution to journalReviewResearchpeer-review

  1. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Factors associated with citation of original articles in 5 high-impact-factor dermatology journals

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Patients with a familial predisposition to hidradenitis suppurativa have a distinct clinical phenotype

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Prenatal, infantile, and childhood tobacco exposure and risk of pediatric psoriasis in the Danish National Birth Cohort offspring

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The use of the humanized monoclonal anti-programmed cell death-1 antibodies pembrolizumab and nivolumab as potent anti-cancer therapies is rapidly increasing. However, since their approval numerous cases of cutaneous reactions have been reported. Cutaneous adverse reactions to these agents have yet to be fully characterized and range from non-specific eruptions to recognizable skin manifestations, which may be localized and vary from mild to life-threatening. This systematic review article provides an overview of the various adverse cutaneous reactions to pembrolizumab and nivolumab therapy and offers suggestions for their management.

Original languageEnglish
JournalJournal of the American Academy of Dermatology
Volume83
Issue number5
Pages (from-to)1415-1424
Number of pages10
ISSN0190-9622
DOIs
Publication statusPublished - 1 Nov 2020

Bibliographical note

Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

    Research areas

  • anti–PD-1, cutaneous adverse reaction, dermatology, immunotherapy, oncology

ID: 59742095